Full-Time

Business Analyst Principal

Updated on 7/12/2026

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

No salary listed

Company Historically Provides H1B Sponsorship

Boston, MA, USA

Hybrid

Four days on-site per week required.

Category
Business & Strategy (1)
Required Skills
Bloomberg
Python
SQL
Java

People at Wellington Management

People at Wellington Management who can refer or advise you

Requirements
  • Minimum 10 years’ experience as a business systems analyst in the financial services industry, with a focus on security analytics, instrument pricing, or performance attribution.
  • Practical understanding of financial instruments including stocks, bonds, swaps, options, futures, forwards, asset-backed securities, and mortgages.
  • Deep understanding of all asset classes and the principles of financial instrument pricing.
  • Strong knowledge of analytics and performance attribution methodologies across asset classes.
  • Proven senior engineering skills, including hands-on experience in software design, development, and architecture.
  • Experience working with analytics and pricing vendors (e.g., Bloomberg, FactSet, MSCI).
  • Exposure to vendor valuation libraries and applications (e.g., Numerix, Calypso, FinCad).
  • Experience with investment data concepts such as holdings, transactions, security master, analytics, and performance.
  • Excellent written and verbal communication skills.
  • Strong analytical and problem-solving skills with high attention to detail.
  • Proven ability to build strong relationships with business partners and drive consensus across teams.
  • Experience writing requirements, functional specifications, use cases, and test plans.
  • Creative, innovative, and focused on continuous improvement.
  • Self-motivated and able to thrive in a fast-paced, result-oriented environment.
  • Ability to work independently and demonstrate ownership of outcomes.
  • Hands-on knowledge of SQL and relational database technology.
  • Expert knowledge of Java and Python are required.
  • Experience supporting critical production applications.
  • Solid understanding of the software development life cycle.
  • Bachelor’s degree required.
  • CFA Institute Claritas Certificate, CFA Charter, or progress toward one is considered an asset.
Responsibilities
  • Act as the lead business analyst for the security analytics platform, with a focus on instrument pricing, analytics, and performance attribution capabilities.
  • Partner with quantitative research and investment teams to understand pricing and attribution methodologies and translate them into functional and technical requirements.
  • Lead initiatives to enhance analytics data quality, model transparency, and system robustness.
  • Collaborate with technology teams to ensure timely and accurate delivery of analytics features and enhancements.
  • Support production systems and act as a subject matter expert for analytics, pricing, and attribution inquiries and issue resolution.
  • Coordinate with internal stakeholders and external vendors during testing, validation, and implementation phases.
  • Maintain comprehensive documentation of business requirements, functional specifications, and support procedures.
  • Drive continuous improvement in analytics workflows, data integration, and user experience.
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$63.1B

Headquarters

Boston, Massachusetts

Founded

1933

People at Wellington Management

People at Wellington Management who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $67M lead investment in Climate First Bank positions Wellington ahead of its potential IPO.
  • Dedicated private climate team expands into food, agriculture, and industrial automation sectors.
  • $90K-$180K Associate hire signals strong growth in Wellington's climate venture strategy.

What critics are saying

  • Passive ESG index funds compress fees, eroding AUM revenue by 5-8% annually within 12-18 months.
  • Climate First Bank IPO failure could trigger $200M+ AUM loss and client mandate withdrawals in 6-12 months.
  • EU reclassifies nonconcessionary climate strategies as high-risk, forcing disclosures and client exits in 9-15 months.

What makes Wellington Management unique

  • Wellington leads climate innovation with $385M first fund focused on tech-enabled climate solutions.
  • The firm uses proprietary CERA tool for geospatial analysis of physical climate risks against client assets.
  • Wellington offers differentiated private climate investing targeting adaptation and mitigation across energy and agriculture.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.